All News

RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
Platelets, ITP

Eltrombopag, a Potential New Treatment for ITP

Jack Cush, MD

A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD),  refractory immune thrombocytopenia (ITP).

Read Article
RheumNow Podcast square

Alive in 2025 (1.10.2025)

Jack Cush, MD

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

Read Article
Teens.adolescents.kids

EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care

Jack Cush, MD

EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.

Read Article
arthritis,gout,autoimmune,Dx,lab

Prevalence of Autoimmune Diseases in the United States

Jack Cush, MD

An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.

Read Article
shingles_0.jpg

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab

MedPage Today

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.

Read Article
CV,risk,MI,heart,cardiac

A Modifiable Vascular Risk in SLE

MedPage Today

Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.

Read Article
Among SLE pts, males have a higher risk of infection compared to females. Males have a (6X) higher prevalence of pneumonia and women have more urinary tract infections. Retrospective study of 119 SLE pts (107 females, 12 males) https://t.co/M12G7hT340 https://t.co/SG7eSGzpXh

Links:

Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential… https://t.co/I3u8tK5EMq https://t.co/VItPWtrPUA
Dr. John Cush RheumNow ( View Tweet)
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential… https://t.co/zebERdPfzV https://t.co/MOIjbhcWSa
Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. https://t.co/IibXiitVY8 https://t.co/XHBQcdcMAE

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: Active Lupus on pred + DMARD w/ (more than skin/Joint) organ & serologic activity- whats your preferred "add-on" drug?

Dr. John Cush RheumNow ( View Tweet)

Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/ug2ZzzSrGi https://t.co/O6r1e8ioO0

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/aNk5pgBpiJ https://t.co/C427ayULng

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 5063 SLE patients, found fibromyalgia (FM) 15.8% (high heterogeneity I2- 98%). SLE pts had a 3.7 fold higher risk of FM. FM in SLE was a confounder in assessing disease activity and treatment response. FM is a frequent comorbidity in SLE https://t.co/0fSIl480PG https://t.co/6ZtAovPVnD

Links:

Dr. John Cush RheumNow ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI

Links:

Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/dr3M3cnjRG https://t.co/1wewEuJRAl

Links:

Dr. John Cush RheumNow ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3

Links:

Dr. John Cush RheumNow ( View Tweet)

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/zLxEOnWjpB https://t.co/I8jBcxO6rH

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×